Most of the major players in the medical device arena, and a few from off the bench, are busy touting new products
and results from a slew of clinical trials at the European Assn. of
Percutaneous Cardiovascular Interventions annual conference, EuroPCR 2010:
Abbott (NYSE:ABT):
- New Data Reinforces Safety Profile of
Abbott’s Market-Leading XIENCE V Drug Eluting Stent:In XIENCE V USA Study, XIENCE V Demonstrates Low Blood Clot Rate
at One Year in Real-World Patient Population;In SPIRIT V Diabetes Trial, XIENCE V Demonstrates Zero Cases of
Stent Thrombosis at One Year in Patients with Diabetes - Abbott’s Investigational MitraClip
System Demonstrates Strong Safety Results and Improved Clinical
Outcomes for Common Causes of Leaky Heart Valves:Preliminary Results Also Show MitraClip Device Maintains
Durability through Two Years in Patients Treated for Mitral
Regurgitation - Abbott’s Groundbreaking Bioresorbable
Technology Continues to Demonstrate Exceptional Clinical
Results:New Six-Month Data on Abbott’s Bioresorbable Vascular Scaffold
Reinforces Its Potential to Be the Next Revolution in
Interventional Cardiology
Abiomed Inc. (NSDQ:ABMD):
- Abiomed Reports Updated USpella Results
Presented at EuroPCR 2010:52% of patients improved New York Heart Association (NYHA)
classification by one or more categories after Impella-supported
complex PCI. Prior to treatment, 63% of patients were in NYHA class
three or four. After treatment, 70% were in NYHA class one or
two.
Cordis Corp. [Johnson & Johnson
(NYSE:JNJ)]:
- NEVO Sirolimus-Eluting Coronary Stent
Continues to Demonstrate Excellent Safety and Efficacy Outcomes in
New Twelve-Month Data:NEVO, Incorporating RES TECHNOLOGY, Continues to Support Excellent
Safety and Efficacy Outcomes vs. the Taxus Liberte According to
Data Presented at EuroPCR 2010
InspireMD Ltd.:
- InspireMD Will Provide a Sneak
Preview of the Next Generation MGuard Prime, a State of the Art Net
Protective Cobalt Chromium Stent System:InspireMD is Also Proud to Announce That MGuard is Now Available
With an Improved Delivery System. Final 6 Month Results of the
MAGICAL Trial and Final 1 Year Results of the INSPIRE Study Will be
Presented During EuroPCR 2010
Medtronic Inc. (NYSE:MDT):
- Medtronic CoreValve System Shows
Long-Term Efficacy and Durability in Pivotal Trial:Market-Leading Transcatheter Aortic Valve Delivers Positive
Clinical Outcomes Through Two Years in Major International Study;
Achieves 10,000-patient Milestone - Multiple European Clinical Registries
Show Important Benefits of Medtronic CoreValve Transcatheter Aortic
Valve System:Data Demonstrates That Revolutionary Treatment for Patients with
Diseased Heart Valves Is Transitioning Successfully into Standard
Clinical Practice throughout Europe - Medtronics Resolute Drug-Eluting Stent
Matches Market-Leading Rival in Large Head-to-Head Study:One-Year Clinical Results from Innovative RESOLUTE All Comers Trial
Show Excellent Performance for Resolute DES in Challenging Patient
Population
NMT Medical Inc. (NSDQ:NMTI):
- NMT Medical Launches Rapid Transport
Septal Implant Delivery System in France:Enhancement Allows Easier Implantation of BioSTAR and STARFlex
Devices
NovoStent Corp.:
- NovoStent Announces 6-Month
Results of SAMBA Femoropopliteal Trial:The SAMBA data showed a 97% Freedom from Target Lesion
Revascularization rate. There were no device related complications
in any of the 38 patients treated in the trial.
OrbusNeich:
- Data Presented at EuroPCR 2010
Demonstrate Effectiveness of OrbusNeich’s Genous” Bio-engineered R
stent” in Diabetic Patients:OrbusNeich today announced that 12-month follow-up data from a
subset analysis of the global e-HEALING registry demonstrate that
the company’s Genous Bio-engineered R stent is effective in
diabetic patients.
St. Jude Medical Inc. (NYSE:STJ):
- St. Jude Medical Announces Initiation of
a Study to Evaluate the Economic Impact of FFR in Europe and
Canada:Country-specific analysis will evaluate the cost effectiveness of
an FFR-guided intervention strategy for patients with multivessel
coronary artery disease in the UK, Germany, France, Italy,
Switzerland, Belgium and Canada; Unique data from each country will
be used to assess the budget and health impact of FFR on its health
care system
Tryton Medical Inc.:
- Tryton Announces Positive Data from
Side Branch System Presented in Symposium at EuroPCR
2010:Tryton Stent Consistently Demonstrates Excellent Results